Sympathetic neural mechanisms of cyclosporine-induced hypertension

American Journal of Hypertension

Volumn 9, Issue 11, 1996, Pages

  Sander, Mikael ^a   Lyson, Teresa ^a   Thomas, Gail D ^a   Victor, Ronald G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

calcineurin; cyclosporine A; hypertension; immunosuppression

Indexed keywords

CALCINEURIN; CALMODULIN; PREDNISONE; RAPAMYCIN;

ADRENERGIC SYSTEM; CONFERENCE PAPER; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0029850994     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-7061(96)00288-9     Document Type: Conference Paper

References (197)

1. Kaye MP: Registry report: International Society for Heart and Lung Transplantation. Clinical Transplants 1991:39-44.
2. Shuster S, Nussenblatt RB, Amor B, et al: Applications for specific diseases, in Kahan BD (ed): Cyclosporine: Applications in Autoimmune Diseases. Grune & Stratton, Philadelphia, 1988, pp 19-345.
3. van Joost T, Bos JD, Heule F, Meinardi MM: Low-dose cyclosporin A in severe psoriasis. A double-blind study. Br J Dermatol 1988;118(2):183-190.
4. van Joost T, Heule F, Korstanje M, et al: Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol 1994;130(5):634-640.
5. Ellis CN, Fradin MS, Messana JM, et al: Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial [see comments]. N Engl J Med 1991; 324(5):277-284.
6. Laburte C, Grossman R, Abi-Rached J, et al: Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994;130(3):366-375.
7. Honeyman JF, Sanchez L, Valdes P: Low-dose cyclosporine A improves severe disabling psoriasis in Latin America. Latin American Multicenter Study. Int J Dermatol 1995;34(8):583-588.
8. Gupta AK, Rocher LL, Schmaltz SP, et al: Short-term changes in renal function, blood pressure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders. Arch Intern Med 1991;151(2): 356-362.
9. Deray G, Benhmida M, Le Hoang P, et al: Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med 1992;117(7): 578-583.
10. Berg KJ, Forre O, Bjerkhoel F, et al: Side effects of cyclosporin A treatment in patients with rheumatoid arthritis. Kidney Int 1986;29(6):1180-1187.
11. Yocum DE, Klippel JH, Wilder RL, et al: Cyclosporin A in severe, treatment-refractory rheumatoid arthritis. A randomized study. Ann Intern Med 1988;109(11) :863-869.
12. Forre O: Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group. Arthritis Rheum 1994;37(10):1506-1512.
13. Kruger K, Schattenkirchner M: Comparison of cyclosporin A and azathioprine in the treatment of rheumatoid arthritis - results of a double-blind multicentre study. Clin Rheumatol 1994;13(2):248-255.
14. Tugwell P, Pincus T, Yocum D, et al: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group [see comments]. N Engl J Med 1995;333(3):137-141.
15. Lichtiger S, Present DH, Kornbluth A, et al: Cyclosporine in severe ulcerative colitis refractory to steroid therapy [see comments]. N Engl J Med 1994;330(26): 1841-1845.
16. Present DH, Lichtiger S: Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 1994;39(2):374-380.
17. Myers BD, Ross J, Newton L, et al: Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311(11):699-705.
18. Berg KJ, Forre O, Djoseland O, et al: Renal side effects of high and low cyclosporin A doses in patients with rheumatoid arthritis. Clin Nephrol 1989;31(5):232-238.
19. Hughes RL: Cyclosporine-related central nervous system toxicity in cardiac transplantation (letter). N Engl J Med 1990;323(6):420-421.
20. Rubin AM: Transient cortical blindness and occipital seizures with cyclosporine toxicity. Transplantation 1989;47(3):572-573.
21. Lane RJM, Roche SE, Leung AAW, et al: Cyclosporine neurotoxicity in cardiac transplant recipients. J Neurol Neuosurg Psychiatry 1988;51:1434-1437.
22. Atkinson K, Biggs J, Darveniz P, Boland J, et al: Cyclosporine-associated central nervous system toxicity after allogenic bone marrow transplantation (letter). N Engl J Med 1984;310:527.
23. Gross MLP, Pearson RM, Sweny P, Moorhead JF: Convulsions associated with cyclosporine A in renal transplant recipients (letter). Br Med J Clin Res Ed 1985; 290:555.
24. Schwartz RB, Bravo SM, Klufas RA, et al: Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. Am J Roentgenol 1995;165(3):627-631.
25. Thompson ME, Shapiro AP, Johnsen AM, et al: New onset of hypertension following cardiac transplantation: a preliminary report and analysis. Transplant Proc 1983;15(suppl 1):2573-2577.
26. Schachter M: Cyclosporine A and hypertension. J Hypertens 1988;6:511-516.
27. Bennett WM, Porter GA: Cyclosporine-associated hypertension. Am J Med 1988;85:131-133.
28. Curtis JJ: Cyclosporine and posttransplant hypertension. J Am Soc Nephrol 1992;2(suppl 12):S243-S245.
29. Loughran T, Jr., Deeg HJ, Dahlberg S, et al: Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graft-versus-host disease prophylaxis. Br J Haematol 1985;59:547-553.
30. Kirk AJ, Omar I, Bateman DN, Dark JH: Cyclosporine-associated hypertension in cardiopulmonary transplantation. The beneficial effect of nifedipine on renal function. Transplantation 1989;48:428-430.
31. Olivari MT, Antolick A, Ring WS: Arterial hypertension in heart transplant recipients treated with triple-drug immunosuppressive therapy. J Heart Transplant 1989;8:34-39.
32. Morrison RJ, Short HD, Noon GP, Frost AE: Hypertension after lung transplantation. J Heart Lung Transplant 1993;12:928-931.
33. Sturrock ND, Lang CC, Struthers AD: Cyclosporin-induced hypertension precedes renal dysfunction and sodium retention in man. J Hypertens 1993;11 (11):1209-1216.
34. Sturrock ND, Lang CC, Baylis PH, Struthers AD: Sequential effects of cyclosporine therapy on blood pressure, renal function and neurohormones. Kidney Int 1994;45(4):1203-1210.
35. Joss DV, Barrett AJ, Kendra JR, et al: Hypertension and convulsions in children receiving cyclosporin A (letter). Lancet 1982;1(8277):906.
36. Reece DE, Frei-Lahr DA, Shepherd JD, et al: Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Bone Marrow Transplant 1991;8(5):393-401.
37. Luke RG, Curtis JJ: Biology and treatment of transplant hypertension, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management, 2nd ed. Raven Press, New York, 1995, pp 2471-2483.
38. Thompson ME, Shapiro AP, Johnsen AM, et al: The contrasting effects of cyclosporin-A and azathioprine on arterial blood pressure and renal function following cardiac transplantation. Int J Cardiol 1986;11(2) :219-229.
39. Barnhart GR, Hastillo A, Goldman MH, et al: A prospective randomized trial of pretransfusion / azathioprine / prednisone versus cyclosporine / prednisone immunosuppression in cardiac transplant recipients: preliminary results. Circulation 1985;72 (3, pt 2): II227-II230.
40. Myers BD, Sibley R, Newton L, et al: The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988;33(2):590-600.
41. Deeg HJ, Storb R, Thomas ED, et al: Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985;65(6):1325-1334.
42. Kone BC, Whelton A, Santos G, et al: Hypertension and renal dysfunction in bone marrow transplant recipients. Q J Med 1988;69(260):985-995.
43. Curtis JJ, Luke RG, Dubovsky E, et al: Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 1986;2(8505):477-479.
44. Chapman JR, Marcen R, Arias M, et al: Hypertension after renal transplantation. A comparison of cyclosporine and conventional immunosuppression. Transplantation 1987;43(6):860-864.
45. Rodier M, Ribstein J, Parer-Richard C, Mimran A: Renal changes associated with cyclosporine in recent type I diabetes mellitus. Hypertension 1991;18 (3):334-340.
46. Mimran A, Mourad G, Ribstein J, Halimi J-M: Cyclosporine-associated hypertension, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management, 2nd ed. Raven Press, New York, 1995, pp 2459-2469.
47. Hill MN, Grossman RA, Feldman HI, et al: Changes in causes of death after renal transplantation, 1966 to 1987. Am J Kidney Dis 1991;17(5):512-518.
48. Vianello A, Mastrosimone S, Calconi G, et al: The role of hypertension as a damaging factor for kidney grafts under cyclosporine therapy. Am J Kidney Dis 1993; 21(5, suppl 2):79-83.
49. Cosio FG, Dillon JJ, Falkenhein ME, et al: Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int 1995;47:1136-1141.
50. Sehgal V, Radhakrishnan J, Appel GB, et al: Progressive renal insufficiency following cardiac transplantation: cyclosporine, lipids, and hypertension. Am J Kidney Dis 1995;26(1):193-201.
51. Frist WH, Stinson EB, Oyer PE, et al: Long-term hemodynamic results after cardiac transplantation. J Thorac Cardiovasc Surg 1987;94(5):685-693.
52. Angermann CE, Spes CH, Willems S, et al: Regression of left ventricular hypertrophy in hypertensive heart transplant recipients treated with enalapril, furosemide, and verapamil. Circulation 1991;84(2):583-593.
53. Ventura HO, Lavie CJ, Messerli FH, et al: Cardiovascular adaptation to cyclosporine-induced hypertension. J Hum Hypertens 1994;8(4):233-237.
54. Bull DA, Hunter GC, Copeland JG, et al: Peripheral vascular disease in heart transplant recipients. J Vasc Surg 1992;16(4):546-553.
55. Randall C, Starling MD, Cody RJ: Cardiac transplant hypertension. Am J Cardiol 1990;65:106-111.
56. The Multiple Sclerosis Study Group: Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group [see comments]. Ann Neurol 1990;27(6):591-605.
57. Schreiber SL, Liu J, Albers MW, et al: Immunophilin-ligand complexes as probes of intracellular signalling pathways. Transplant Proc 1991;23:2839-2844.
58. Cohen DJ, Loertscher R, Rubin MF, et al: Cyclosporine. A new immunosuppressive agent for organ transplantation. Ann Intern Med 1984;101:667-682.
59. Hess AD, Esa AH, Colombani, et al: Mechanisms of action of cyclosporine, in Kahan BD (ed): Cyclosporine: Nature of the Agent and its Immunologic Actions. Grune & Stratton, Philadelphia, 1988, pp 29-309.
60. Gluckman E, Esperou-Bourdeau H, Baruchel A, et al: Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood 1992; 79(10):2540-2546.
61. Schreiber SL: Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991;251(4991):283-287.
62. Schreiber SL, Crabtree GR: The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13(4):136-142.
63. Kunz J, Hall MN: Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. Trends Biochem Sci 1993;18(9):334-338.
64. Martinet Y, Pinkston P, Saltini C, et al: Evaluation of the in vitro and in vivo effects of cyclosporine on the lung T-lymphocyte alveolitis of active pulmonary sarcoidosis. Am Rev Respir Dis 1988;138(5):1242-1248.
65. June CH, Jackson KM, Ledbetter JA, et al: Two distinct mechanisms of interleukin-2 gene expression in human T lymphocytes. J Autoimmun 1989;2(suppl):55-65.
66. June CH, Ledbetter JA, Lindsten T, Thompson CB: Evidence for the involvement of three distinct signals in the induction of IL-2 gene expression in human T lymphocytes. J Immunol 1989;143(1):153-161.
67. Handschumacher RE, Harding MW, Rice J, et al: Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984;226(4674):544-547.
68. Walsh CT, Zydowsky LD, McKeon FD: Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction. J Biol Chem 1992;267(19):13115-13118.
69. Takahashi N, Hayano T, Suzuki M: Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 1989;337(6206):473-475.
70. Bram RJ, Hung DT, Martin PK, et al: Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol 1993;13(8):4760-4769.
71. Harding MW, Galat A, Uehling DE, Schreiber SL: A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989;341 (6244):758-760.
72. Siekierka JJ, Hung SH, Poe M, et al: A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989;341(6244):755-757.
73. Bierer BE, Mattila PS, Standaert RF, et al: Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci USA 1990;87(23):9231-9235.
74. Fruman DA, Klee CB, Bierer BE, Burakoff SJ: Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 1992;89(9):3686-3690.
75. Liu J, Albers MW, Wandless TJ, et al: Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry 1992;31(16):3896-3901.
76. Liu J, Farmer JD, Jr., Lane WS, et al: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991;66(4):807-815.
77. Swanson SK, Born T, Zydowsky LD, et al: Cyclosporin-mediated inhibition of bovine calcineurin by cyclophilins A and B. Proc Natl Acad Sci USA 1992;89(9):3741-3745.
78. Clipstone NA, Crabtree GR: Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992;357(6380):695-697.
79. O'Keefe SJ, Tamura J Kincaid RL, et al: FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992;357(6380):692-694.
80. Jain J, Miner Z, Rao A: Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells. J Immunol 1993;151(2):837-848.
81. Jain J, McCaffrey PG, Miner Z, et al: The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 1993; 365(6444):352-355.
82. McCaffrey PG, Perrino BA, Soderling TR, Rao A: NF-ATp, a T lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs. J Biol Chem 1993;268(5):3747-3752.
83. Park J, Yaseen NR, Hogan PG, et al: Phosphorylation of the transcription factor NFATp inhibits its DNA binding activity in cyclosporin A-treated human B and T cells. J Biol Chem 1995;270(35):20653-20659.
84. Ruff VA, Leach KL: Direct demonstration of NFATp dephosphorylation and nuclear localization in activated HT-2 cells using a specific NFATp polyclonal antibody. J Biol Chem 1995;270(38):22602-22607.
85. Ho S, Timmerman L, Northrop J, Crabtree GR: Cloning and characterization of NF-ATc and NF-ATp: the cytoplasmic components of NF-AT. Adv Exp Med Biol 1994;365:167-173.
86. Schumacher A, Nordheim A: Progress towards a molecular understanding of cyclosporin A-mediated immunosuppression. Clin Invest 1992;70(9):773-779.
87. Kubo M, Kincaid RL, Ransom JT: Activation of the interleukin-4 gene is controlled by the unique calcineurin-dependent transcriptional factor NF(P). J Biol Chem 1994;269(30):19441-19446.
88. 2+/calmodulin-activated, phosphoprotein phosphatase calcineurin is sufficient for positive transcriptional regulation of the mouse IL-4 gene. Int Immunol 1994;6(2):179-188.
89. Fruman DA, Bierer BE, Benes JE, et al: The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. J Immunol 1995;154(4):1846-1851.
90. McCaffrey PG, Goldfeld AE, Rao A: The role of NFATp in cyclosporin A-sensitive tumor necrosis factor-alpha gene transcription. J Biol Chem 1994; 269(48):30445-30450.
91. Pai SY, Fruman DA, Leong T, et al: Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood 1994;84(11):3974-3979.
92. Batiuk TD, Pazderka F, Enns J, et al: Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J Clin Invest 1995; 96(3):1254-1260.
93. Batiuk TD, Pazderka F, Halloran PF: Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Transplantation 1995; 59(10):1400-1404.
94. Brown EJ, Albers MW, Shin TB, et al: A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994;369(6483):756-758.
95. Albers MW, Brown EJ, Tanaka A, et al: An FKBP-rapamycin-sensitive, cyclin-dependent kinase activity that correlates with the FKBP-rapamycin-induced G1 arrest point in MG-63 cells. Ann NY Acad Sci 1993; 696:54-62.
96. Dumont FJ, Altmeyer A, Kastner C, et al: Relationship between multiple biologic effects of rapamycin and the inhibition of pp70S6 protein kinase activity. Analysis in mutant clones of a T cell lymphoma. J Immunol 1994;152(3):992-1003.
97. Ferrari S, Pearson RB, Siegmann M, et al: The immunosuppressant rapamycin induces inactivation of p70s6k through dephosphorylation of a novel set of sites. J Biol Chem 1993;268(22):16091-16094.
98. Kuo CJ, Chung J, Fiorentino DF, et al: Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992;358(6381):70-73.
99. Klee CB, Crouch TH, Krinks MH: Calcineurin: a calcium- and calmodulin-binding protein of the nervous system. Proc Natl Acad Sci USA 1979;76:6270-6273.
100. Klee CB, Draetta GF, Hubbard MJ: Calcineurin, in Meister A (ed): Advances in Enzymology and Related Areas of Molecular Biology. John Wiley and Sons, New York, 1988;61:149-200.
101. Koletsky AJ, Harding MW, Handschumacher RE: Cyclophilin: distribution and variant properties in normal and neoplastic tissues. J Immunol 1986; 137(3):1054-1059.
102. Dawson TM, Steiner JP, Lyons WE, et al: The immunophilins, FK506 binding protein and cyclophilin, are discretely localized in the brain: relationship to calcineurin. Neuroscience 1994;62(2):569-580.
103. Steiner JP, Dawson TM, Fotuhi M, et al: High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature 1992;358(6387):584-587.
104. Su Q, Zhao M, Weber E, et al: Distribution and activity of calcineurin in rat tissues. Evidence for post-transcriptional regulation of testis-specific calcineurin B. Eur J Biochem 1995;230(2):469-474.
105. Fraser Ed, Walsh MP: Dephosphorylation of calponin by type 2B protein phosphatase. Biochemistry 1995; 34(28):9151-9158.
106. Buttini M, Limonta S, Luyten M, Boddeke H: Distribution of calcineurin A isoenzyme mRNAs in rat thymus and kidney. Histochem J 1995;27(4):291-299.
107. Otsuka M, Terada Y, Yang T, et al: Localization of cyclophilin A and cyclophilin C mRNA in murine kidney using RT-PCR. Kidney Int 1994;45(5):1340-1345.
108. Tumlin JA, Someren JT, Swanson CE, Lea JP: Expression of calcineurin activity and alpha-subunit isoforms in specific segments of the rat nephron. Am J Physiol 1995;269(4, pt 2):F558-F563.
109. Bellet M, Cabrol C, Sassano P, et al: Systemic hypertension after cardiac transplantation: effect of cyclosporine on the renin-angiotensin-aldosterone system. Am J Cardiol 1985;56:927-931.
110. Feutren G, Mihatsch MJ: Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International kidney biopsy registry of cyclosporine in autoimmune diseases [see comments]. N Engl J Med 1992;326(25):1654-1660.
111. Zietse R, Balk AH, Meeter K, et al: Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 1994;14(1):1-5.
112. Bantle JP, Boudreau RJ, Ferris TF: Suppression of plasma renin activity by cyclosporine. Am J Med 1987; 83(1)59-64.
113. Singer DR, Markandu ND, Buckley MG, et al: Blood pressure and endocrine responses to changes in dietary sodium intake in cardiac transplant recipients. Implications for the control of sodium balance. Circulation 1994;89(3):1153-1159.
114. Thomson SC, Tucker BJ, Gabbai F, Blantz RC: Functional effects on glomerular hemodynamics of short-term chronic cyclosporine in male rats. J Clin Invest 1989;83(3):960-969.
115. Sigal NH, Dumont F, Durette P, et al: Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J Exp Med 1991;173(3):619-628.
116. Sigal NH, Dumont FJ: Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992;10:519-560.
117. Lanese DM, Conger JD: Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993; 91(5):2144-2149.
118. Dumont FJ, Staruch MJ, Koprak SL, et al: The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 1992; 176(3):751-760.
119. Textor SC, Burnett JC, Jr., Romero JC, et al: Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int 1995;47:1426-1433.
120. Richards NT, Poston L, Hilton PJ: Cyclosporine A inhibits endothelium-dependent, prostanoid-induced relaxation in human subcutaneous resistance vessels. J Hypertens 1990;8:159-163.
121. Roullet JB, Xue H, McCarron DA, et al: Vascular mechanisms of cyclosporine-induced hypertension in the rat. J Clin Invest 1994;93(5):2244-2250.
122. Amore A, Gianoglio B, Ghigo D, et al: A possible role for nitric oxide in modulating the functional cyclosporine toxicity by arginine. Kidney Int 1995;47:1507-1514.
123. Dawson TM, Steiner JP, Dawson VL, et al: Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity [see comments]. Proc Natl Acad Sci USA 1993;90(21):9808-9812.
124. Marumo T, Nakaki T, Hishikawa K, et al: Cyclosporine A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension 1995;25(4, pt 2):764-768.
125. Mittal CK, Jadhav AL: Calcium-dependent inhibition of constitutive nitric oxide synthase. Biochem Biophys Res Commun 1994;203(1):8-15.
126. Meyer-Lehnert H, Schrier RW: Potential mechanism for cyclosporine-induced vascular smooth muscle contraction. Hypertension 1989;13:352-360.
127. Bokemeyer D, Kramer HJ, Meyer-Lehnert H: Atrial natriuretic peptide blunts the cellular effects of cyclosporine in smooth muscle. Hypertension 1993; 21(2):166-172.
128. Bokemeyer D, Friedrichs U, Backer A, et al: Cyclosporine A enhances total cell calcium independent of Na-K-ATPase in vascular smooth muscle cells. Clin Invest 1994;72(12):992-995.
129. Lamb FS, Webb RC: Cyclosporine augments reactivity of isolated blood vessels. Life Sci 1987;40(26):2571-2578.
130. Xue H, Bukoski RD, McCarron DA, Bennett WM: Induction of contraction in isolated rat aorta by cyclosporine. Transplantation 1987;43:715-718.
131. Rego A, Vargas R, Suarez KR, et al: Mechanism of Cyclosporine potentiation of vasoconstriction of the isolated rat mesenteric arterial bed: role of extracellular calcium. J Pharmacol Exp Ther 1990;254:799-808.
132. Brillantes AB, Ondrias K, Scott A, et al: Stabilization of calcium release channel (Ryanodine Receptor) function by FK506-binding protein. Cell 1994;77(4):513-523.
133. Cameron AM, Steiner JP, Sabatini DM, et al: Immunophilin FK506 binding protein associated with inositol 1,4,5-triphosphate receptor modulates calcium flux. Proc Natl Acad Sci USA 1995;92(5):1784-1788.
134. Garr MD, Paller MS: Cyclosporine augments renal but not systemic vascular reactivity. Am J Physiol 1990; 258(27):F211-F217.
135. Haas GJ, Wooding-Scott M, Binkley PF, et al: Effects of successful cardiac transplantation on plasma endothelin. Am J Cardiol 1993;71(2):237-240.
136. Textor SC, Powell-Smith L, Telles T: Altered pressor responses to NE and ANG II during cyclosporine A administration to conscious rats. Am J Physiol 1990; 258(3, pt 2):H854-H860.
137. Kaye D, Thompson J, Jennings G, Esler M: Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation. Circulation 1993;88:1101-1109.
138. Takeda Y, Miyamori I, Yoneda T, Takeda R: Increased concentration of endothelin messenger RNA in the mesenteric arteries of cyclosporine-induced hypertensive rats. Am J Hypertens 1993;6(5, pt 1):427-430.
139. Bunchman TE, Brookshire CA: Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 1991;88(1):310-314.
140. Grieff M, Loertscher R, Shohaib SA, Stewart DJ: Cyclosporine-induced elevation in circulating endothelin-1 in patients with solid-organ transplants. Transplantation 1993;56(4):880-884.
141. Stein CM, He H, Pincus T, Wood AJ: Cyclosporine impairs vasodilation without increased sympathetic activity in humans. Hypertension 1995;26(4):705-710.
142. Murray BM, Paller MS, Ferris TF: Effects of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 1985;28:767-774.
143. Scherrer U, Vissing SF, Morgan BJ, et al: Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990;323: 693-699.
144. Chiu PJ, Vemulapalli S, Sabin C, et al: Sympathoadrenal stimulation, not endothelin, plays a role in acute pressor response to cyclosporine in anesthetized rats. J Pharmacol Exp Ther 1992;261:994-999.
145. Morgan BJ, Lyson T, Scherrer U, Victor RG: Cyclosporine causes sympathetically mediated elevations in arterial pressure in rats. Hypertension 1991; 18:458-466.
146. Cavero PG, Sudhir K, Galli F, et al: Effect of orthotopic cardiac transplantation on peripheral vascular function in congestive heart failure: influence of cyclosporine therapy. Am Heart J 1994;127(6):1581-1587.
147. Tronc F, Carrier M, Pelletier CL: mechanism of hind limb vasoconstriction due to cyclosporine A in the dog. Circ Res 1992;71:1159-1164.
148. Moss NG, Powell SL, Falk RJ: Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc Natl Acad Sci USA 1985;82:8222-8226.
149. Lyson T, McMullan DM, Ermel LD, et al: Mechanism of cyclosporine-induced sympathetic activation and acute hypertension in rats. Hypertension 1994;23:667-675.
150. Lyson T, Ermel LD, Belshaw PJ, et al: Cyclosporine-and FK-506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signalling. Circ Res 1993;73:596-602.
151. Jacobsen TN, Morgan BJ, Scherrer U, et al: Relative contributions of cardopulmonary and sinoaortic baroreflexes in causing sympathetic activation in the human skeletal muscle circulation during orthostatic stress. Circ Res 1993;73:367-378.
152. Seals DR, Suwarno NO, Joyner MJ, et al: Respiratory modulation of muscle sympathetic nerve activity in intact and lung denervated humans. Circ Res 1993; 72:440-454.
153. Textor SC: De novo hypertension after liver transplantation [clinical conference]. Hypertension 1993; 22(2):257-267.
154. Weir MR: Therapeutic benefits of calcium channel blockers in cyclosporine-treated organ transplant recipients: blood pressure control and immunosuppression. Am J Med 1991;90(5A):32S-36S.
155. Peters DH, Fitton A, Plosker GL, Faulds D: Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46(4):746-794.
156. First MR, Neylan JF, Rocher LL, Tejani A: Hypertension after renal transplantation. J Am Soc Nephrol 1994;4(8, suppl):S30-S36.
157. Sturrock ND, Lang CC, MacFarlane LJ, et al: Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males. J Hypertens 1995; 13(6):667-673.
158. Ryffel B, Weber E, Mihatsch MJ: Nephrotoxicity of immunosuppressants in rats: comparison of macrolides with cyclosporin. Exp Nephrol 1994;2(6):324-333.
159. Su Q, Weber L, Le Hir M, et al: Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase. Ren Physiol Biochem 1995;18(3):128-139.
160. +-AT-Pase activity in renal tubule cells. Proc Natl Acad Sci USA 1992;89(16):7394-7397.
161. +-ATPaSe activity by FK506 involves calcineurin. Kidney Int 1994;46(3): 647-652.
162. Fast DJ, Lynch RC, Leu RW: Cyclosporin A inhibits nitric oxide production by L929 cells in response to tumor necrosis factor and interferon-gamma. J Interferon Res 1993;13(3):235-240.
163. Zhang J, Steiner JP: Nitric oxide synthase, immunophilins and poly(ADP-ribose) synthetase: novel targets for the development of neuroprotective drugs. Neurol Res 1995;17(4):285-288.
164. Busse R, Luckhoff A, Mulsch A: Cellular mechanisms controlling EDRF / NO formation in endothelial cells. Basic Res Cardiol 1991;2:7-16.
165. Forstermann U, Pollock JS, Schmidt HH, et al: Calmodulin-dependent endothelium-derived relaxing factor / nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991; 88(5):1788-1792.
166. Haug C, Duell T, Lenich A, et al: Elevated plasma endothelin concentrations in cyclosporine-treated patients after bone marrow transplantation. Bone Marrow Transplant 1995;16(1):191-194.
167. Sudhir K, DeMarco T, Kumar S, et al: Transcoronary and pulmonary vascular dynamics of endothelin-1 in heart transplant recipients. J Heart Lung Transplant 1995;14(2):230-235.
168. Takeda Y, Miyamori I, Wu P, et al: Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension 1995;26(6, pt 1):932-936.
169. Elam M, Casale R, La Rovere MT, et al: Is sympathetic neural hyperactivity in chronic heart failure affected by heart transplantation? Eur Heart J 1993;14(4):521-525.
170. Baily RG, Davis D, Clemson B, Zelis R: Normalization of the norepinephrine kinetic response to orthostatic stress after cardiac transplantation. Am J Cardiol 1994; 74(6):624-625.
171. Andresen MC, Kunze DL: Nucleus tractus solitarius - gateway to neural circulatory control. Ann Rev Physiol 1994;56:93-116.
172. Mayer ML, Westbrook GL: The physiology of excitatory amino acids in the vertebrate central nervous system. Prog Neurobiol 1987;28:197-276.
173. Sved AF, Gordon FJ: Amino acids as central neurotransmitters in the baroreceptor reflex pathway. News in Physiological Sciences 1994;9:243-246.
174. Radhakrishnan, Henry JL: Excitatory amino acid receptor mediation of sensory inputs to functionally identified dorsal horn neurons in cat spinal cord. Science 1993;55:521-544.
175. Guyenet PG, Filtz TM, Donaldson SR: Role of excitatory amino acids in rat vagal and sympathetic baroreflexes. Brain Res 1987;407:272-284.
176. Yoshimura M, Jessell T: Amino acid-mediated EPSPs at primary afferent synapses with substantia gelatinosa neurones in the rat spinal cord. J Physiol (Lond) 1990;430:315-335.
177. Hamill OP, Marty A, Neher E, et al: Improved patchclamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Arch 1981;391:85-100.
178. Lieberman DN, Mody I: Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. Nature 1994;369(6477):235-239.
179. King MM, Huang CY, Chock PB, et al: Mammalian brain phosphoproteins as substrates for calcineurin. J Biol Chem 1984;259:8080-8083.
180. Nichols RA, Suplick GR, Brown JM: Calcineurin-mediated protein dephosphorylation in brain nerve terminals regulates the release of glutamate. J Biol Chem 1994;269:23817-23823.
181. Victor RG, Thomas GD, Marban E, O'Rourke B: Presynaptic modulation of cortical synaptic activity by calcineurin. Proc Natl Acad Sci USA 1995;92(14): 6269-6273.
182. Sihra TS, Nairn AC, Kloppenburg P, et al: A role for calcineurin (protein phosphatase-2B) in the regulation of glutamate release. Biochem Biophys Res Commun 1995;212(2):609-616.
183. van der Schaaf MR, Hene RJ, Floor M, et al: Hypertension after renal transplantation. Calcium channel or converting enzyme blockade? Hypertension 1995; 25(1):77-81.
184. Textor SC, Schwartz L, Wilson DJ, et al: Systemic and renal effects of nifedipine in cyclosporine-associated hypertension. Hypertension 1994;23(1, suppl):I220-I224.
185. Schweizer GK, Hartmann A, Kober G, et al: Chronic angiotensin-converting enzyme inhibition may improve sodium excretion in cardiac transplant hypertension. Transplantation 1995;59(7):999-1004.
186. Sennesael J, Lamote J, Violet I, et al: Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients. Hypertension 1995;26(3): 436-444.
187. Barenbrock M, Colmorgen U, Firschka E, et al: A multicenter, randomized, double-blind, placebo-controlled, two-year trial to study the effect of nitrendipine on chronic renal transplant function. Clin Nephrol 1995;43(6):388-391.
188. Armitage JM, Kormos RL, Fung J, Starzl TE: The clinical trial of FK506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc 1991;23:3054-3057.
189. Armitage JM, Kormos RL, Morita S, et al: Clinical Trial of FK 506 Immunosuppression in adult cardiac transplantation. Ann Thorac Surg 1992;54(2):205-210.
190. Armitage JM, Fricker FJ, del Nido P, et al: A decade (1982 to 1992) of pediatric cardiac transplantation and the impact of FK 506 immunosuppression. J Thorac Cardiovasc Surg 1993;105(3):464-472.
191. Textor SC, Wiesner R, Wilson DJ, et al: Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993;55(6):1332-1339.
192. European FK506 Multicentre Liver Study Group: Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group [see comments]. Lancet 1994;344(8920):423-428.
193. The U.S. Multicenter F506 Liver Study Group: A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group [see comments]. N Engl J Med 1994;331(17):1110-1115.
194. McDiarmid SV, Colonna JO, Shaked A, et al: A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. Transplantation 1993;56(4):847-853.
195. McDiarmid SV, Busuttil RW, Ascher NL, et al: FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. Transplantation 1995;59(4):530-536.
196. Neuhaus P, Blumhardt G, Bechstein WO, et al: Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. Transplantation 1995; 59(1):31-40.
197. Tu Y, Stepkowski SM, Chou TC, Kahan BD: The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice. Transplantation 1995;59(2):177-183.